Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 480 results for "Victoza"

More LEADER: Liraglutide Delays Progression of Renal Events

MUNICH The glucagonlike-peptide 2 (GLP-1) agonist liraglutide ( Victoza , Novo Nordisk) delays progression of renal events — in particular, new-onset persistent macroalbuminuria — in patients with type 2 diabetes, according to the latest data ... Diabetes Care, 6 days ago

36 images for Victoza

DataMonitor HealthCare, 4 days ago
Pharma Letter, 1 week ago
Pharma Letter, 3 days ago
BioPharma Dive, 1 week ago
FiercePharma, 1 month ago
Pharmafile, 1 month ago
FiercePharma, 2 months ago
diaTribe, 2 months ago
Nasdaq, 2 months ago
diaTribe, 2 months ago

Liraglutide reduces progression of kidney damage

Treatment with liraglutide (Victoza) reduces the progression of kidney damage when added to standard of care in adults with type 2 diabetes at high cardiovascular risk, according to data presented at the European Association for the study of ...
 Prescriber1 week ago Victoza® lowers the risk of microvascular events in the kidney in adults with type 2 diabetes at high CV risk  PharmiWeb1 week ago Victoza® lowered the progression of kidney damage in adults with type 2 diabetes at high CV risk  PR Newswire India1 week ago Victoza® lowers progression of kidney damage in diabetic adults at high CV risk  Hospital Pharmacy Europe1 week ago
BioPharma Dive

Novo's Victoza follow-on showing heart benefits

Dive Brief: Novo Nordisk announced positive data for its once-weekly glucagon-like peptide (GLP)-1 semaglutide at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Germany Friday morning. Results from the ...
 BioPharma Dive1 week ago Novo Nordisk stokes GLP-1 hopes as weekly semaglutide slashes heart risks by 26%  FiercePharma1 week ago Novo pits prospect semaglutide against Victoza, Jardiance  FiercePharma1 month ago Novo's Victoza Diabetes Medicine Rebuffed by Express Scripts  Bloomberg1 month ago
Monthly Prescribing Reference

Diabetes Drug Victoza Might Not Help Advanced Heart Failure Patients

By Steven Reinberg HealthDay Reporter TUESDAY, Aug. 2, 2016 (HealthDay News) -- The diabetes drug liraglutide (Victoza) doesn't appear to improve heart function in patients with advanced heart failure, a new study finds. The theory for this trial ...
 US News & World Report1 month ago Liraglutide Not Beneficial in Advanced Heart Failure  Physician's Briefing1 month ago No Beneficial Outcomes With Liraglutide Tx in Advanced Heart Failure  Monthly Prescribing Reference1 month ago Diabetes Drug and Advanced Heart Failure Patients  WebMD1 month ago

Novo Nordisk A/S 2Q 2016 -- Forecast

=== Sales: -NovoRapid/ 2nd Quarter -Total -Victoza -Levemir NovoLog AVERAGE 28,291 5,001 4,569 5,202 Prev. Year 27,059 4,486 4,522 ...
 Morningstar.com1 month ago NOVO NORDISK A/S : 2Q Net Profit Surges 19%  4 Traders1 month ago NOVO NORDISK A/S : 2Q 2016 -- Forecast  4 Traders1 month ago Novo Nordisk's 2Q Net Profit Surges 19%  Investors Hub1 month ago
DataMonitor HealthCare

EASD 2016: Renal benefit seen with Victoza in LEADER 3 unlikely to lead to label expansion

Additional data from Victoza's (liraglutide; Novo Nordisk) LEADER 3 cardiovascular outcomes trial in type 2 diabetes were presented on 15 September 2016 at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD 2016).
 DataMonitor HealthCare4 days ago Trial Scorecard: FIGHT  Healio2 weeks ago Victoza May Reduce Heart Disease Risk  Diabetes Forecast2 weeks ago Novo Nordisk diabetes drug Victoza fails to reduce heart failure risk  Pharmafile1 month ago
Pharma Letter

Semaglutide and Victoza data show Novo Nordisk progress in type 2 diabetes

Novo Nordisk has presented promising data both on a Phase III drug and an existing product at
 Pharma Letter1 week ago Novo Nordisk A/S Focuses on New Drugs  Motley Fool1 month ago Novo Nordisk sees pricing challenges 'intensifying'  BioPharma Dive1 month ago Novo sees unexpected Q2 China bump  FiercePharma1 month ago

Victoza (liraglutide)

GENERIC NAME: liraglutide BRAND NAME: Victoza PRESCRIPTION: Yes GENERIC AVAILABLE: No USES: WARNING (BLACK BOX WARNING): Victoza causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rats and mice. It is ...
 MedicineNet.com1 week ago Diabetes Medicine Victoza in Clinical Trial for Parkinson's Disease Treatment  Parkinson'sNewsToday.com1 week ago Scottish Medicines Consortium liraglutide (Victoza)  FirstWord Pharma1 week ago
BioPharma Dive

Novo Nordisk faces delay for insulin combo

Dive Brief: Novo Nordisk announced on Friday its fixed-dose combination of Tresiba, a type of insulin degludec, and Victoza (liraglutide), its GLP-1 inhibitor, has been delayed by the U.S. Food and Drug Administration. A final decision for the ...
 BioPharma Dive2 weeks ago New insulin product reflects well on Novo Nordisk financial results  Copenhagen Post1 month ago

Report finds Sanofi GLP-1 med has safety edge over Victoza

Having just won an FDA nod for its GLP-1 diabetes contender Adlyxin, Sanofi will be going up against some entrenched rivals in its fight for market share. But new data from healthcare informatics firm Advera Health show it might have a safety edge ...
 FiercePharma1 month ago Sanofi Should Be Thinking Longer Duration In GLP-1s  Seeking Alpha1 month ago Monthly News Roundup - July 2016  Drugs.com1 month ago New diabetes drug up against leading brands  Formulary Journal1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Victoza
Get updated on latest news & your favorite topics right in your inbox!
More     Less